Welcome to Evently

Lorem ipsum proin gravida nibh vel veali quetean sollic lorem quis bibendum nibh vel velit.

Evently

Stay Connected & Follow us

Simply enter your keyword and we will help you find what you need.

What are you looking for?

Image Alt
  /  About us

About us

Over the last twenty-five years, academic research has been one of the major driving forces behind the spectacular development of gene therapy for rare or acquired diseases. Due to the success of recent clinical trials of the last generations of gene therapy products to treat rare genetic diseases and to favorable orphan drug legislation in both Europe and the United States, the biotechnology and pharmaceutical industry is now heavily investing in the field, giving hope to become standard clinical practice.

The Gene Therapy Area of Major Interest (DIM Gene Therapy) and Imagine institute, launch the first edition of Gene Therapy for Rare Monogenic Diseases, an international symposium dedicated to recent knowledge and progress in the field to ensure faster and more efficacious development of therapies for diseases with high unmet medical needs. With 200 intended key actors, this two-days event is the unique opportunity to discover the latest gene therapy trends and to see emerge high-potential collaborations.

Over the last twenty-five years, academic research has been one of the major driving forces behind the spectacular development of gene therapy for rare or acquired diseases. Due to the success of recent clinical trials of the last generations of gene therapy products to treat rare genetic diseases and to favorable orphan drug legislation in both Europe and the United States, the biotechnology and pharmaceutical industry is now heavily investing in the field, giving hope to become standard clinical practice.

The Gene Therapy Area of Major Interest (DIM Gene Therapy) and Imagine institute, launch the first edition of Gene Therapy for Rare Monogenic Diseases, an international symposium dedicated to recent knowledge and progress in the field to ensure faster and more efficacious development of therapies for diseases with high unmet medical needs. With 200 intended key actors, this two-days event is the unique opportunity to discover the latest gene therapy trends and to see emerge high-potential collaborations.

Imagine Institute

Imagine Institute of Genetic Diseases is a research and innovative healthcare institute of a new type. Located on the campus of the Necker Enfants Malades Hospital in Paris, it brings together, around the patients, over 900 researchers, physicians and healthcare professionals, work together around the patients to better understand, diagnose, and treat genetic diseases. At the forefront of experimental and clinical expertise in gene therapy, Imagine Institute manages the Gene Therapy Area of Major Interest (DIM Gene Therapy).

What is the DIM ?

The Paris Region is a pioneer in the field of gene therapy with the first gene therapy protocol to treat children with severe immunodeficiency (X-SCID), developed in 1999 by Pr. Alain Fischer, Marina Cavazzana and Salima Hacein-Bey and launched at the Necker – Enfants Malades Hospital.
The Area of Major Interest (DIM) is the result of a structuring policy of the Paris Region to foster innovation by leveraging the excellence of Paris Region teams. The DIM Gene therapy was labelled in 2017 among 8 other DIM for a time-period of 4 years (2017-2020).
Coordinated by Pr Marina Cavazzana, the DIM Gene Therapy is a network of public and private stakeholders with the aim to accelerate the development of gene therapy to reinforce, in the light of personalized medicine, it grades among the most promising and innovative therapeutic strategies. The financed research projects in the field of gene therapy aim to bring multidisciplinary expertise with the prospect of clinical trials and to develop promising therapeutic approach becoming innovative solutions available for patients.

Right Parallax Background Element